Core Viewpoint - Baize Medical (02609) has seen a significant stock price increase of over 50%, reaching a new high of 17.06 HKD, with a cumulative rise of 130% over the past two trading days [1] Company Summary - Baize Medical is a service provider in the "full-cycle medical services for tumors" sector, offering services such as screening, diagnosis, treatment, and rehabilitation [1] - The company has successfully operated eight hospitals across five provinces and cities, including Beijing, Tianjin, Anhui, Shanxi, and Henan [1] - In the first half of the year, Baize Medical reported a revenue of 575 million RMB, reflecting a year-on-year increase of 0.66% [1] - The company experienced a shareholder loss of 27.62 million RMB, which represents a year-on-year increase of 139.18% in losses [1] Market Activity - The stock price of Baize Medical has surged by 58.01% to 16.19 HKD, with a trading volume of 1.437 billion HKD, and the total market capitalization has surpassed 20 billion HKD [1] - The company has been included in the Hong Kong Stock Connect list, effective from September 8, which has contributed to the increased trading activity [1] - The current percentage of Baize Medical shares held through the Hong Kong Stock Connect is 0.21% [1]
港股异动 | 佰泽医疗(02609)再暴涨50%创新高 两个交易日股价飙升1.4倍 总市值突破200亿港元